Equities researchers at Morgan Stanley started coverage on shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) in a report released on Friday, MarketBeat Ratings reports. The firm set an “overweight” rating and a $26.00 price target on the specialty pharmaceutical company’s stock. Morgan Stanley’s price objective points to a potential upside of 39.04% from the stock’s current price.

Several other analysts also recently issued reports on the company. Deutsche Bank AG reissued a “hold” rating and issued a $24.00 price target on shares of AMAG Pharmaceuticals in a research note on Thursday, August 31st. BidaskClub downgraded AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Cowen and Company reissued a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Thursday, August 10th. Zacks Investment Research downgraded AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 26th. Finally, ValuEngine raised AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, July 25th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and three have issued a buy rating to the company. AMAG Pharmaceuticals presently has an average rating of “Hold” and an average price target of $27.92.

Shares of AMAG Pharmaceuticals (AMAG) traded up 4.55% on Friday, reaching $19.55. The company’s stock had a trading volume of 824,891 shares. The company’s market cap is $689.88 million. The company has a 50 day moving average price of $18.12 and a 200 day moving average price of $20.03. AMAG Pharmaceuticals has a 52-week low of $16.00 and a 52-week high of $36.83.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. The firm had revenue of $158.39 million for the quarter, compared to the consensus estimate of $158.83 million. During the same quarter last year, the business posted $1.45 EPS. The company’s revenue for the quarter was up 24.3% on a year-over-year basis. On average, analysts anticipate that AMAG Pharmaceuticals will post ($1.38) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/09/08/amag-pharmaceuticals-inc-amag-now-covered-by-analysts-at-morgan-stanley.html.

In related news, SVP Julie Krop sold 4,938 shares of AMAG Pharmaceuticals stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $20.00, for a total transaction of $98,760.00. Following the completion of the transaction, the senior vice president now owns 28,336 shares in the company, valued at $566,720. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 3.80% of the company’s stock.

A number of institutional investors have recently bought and sold shares of AMAG. State of Alaska Department of Revenue grew its holdings in AMAG Pharmaceuticals by 81.3% during the second quarter. State of Alaska Department of Revenue now owns 6,871 shares of the specialty pharmaceutical company’s stock worth $126,000 after purchasing an additional 3,081 shares during the period. Municipal Employees Retirement System of Michigan grew its holdings in AMAG Pharmaceuticals by 6.6% during the second quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock worth $152,000 after purchasing an additional 510 shares during the period. Advisors Asset Management Inc. grew its holdings in AMAG Pharmaceuticals by 259.9% during the first quarter. Advisors Asset Management Inc. now owns 6,931 shares of the specialty pharmaceutical company’s stock worth $156,000 after purchasing an additional 5,005 shares during the period. Mason Street Advisors LLC grew its holdings in AMAG Pharmaceuticals by 7.4% during the first quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock worth $181,000 after purchasing an additional 554 shares during the period. Finally, Sei Investments Co. grew its holdings in AMAG Pharmaceuticals by 0.7% during the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock worth $188,000 after purchasing an additional 54 shares during the period.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.